By Reuters
NYT Business Day
Swiss drugmaker Novartis boosted its 2019 forecasts on Tuesday after beating third-quarter expectations, a feat helped by the sales debut of gene therapy Zolgensma, the world's most expensive one-time treatment.
Published date: October 22, 2019 at 08:57AM
Reuters
New York Times article
No comments:
Post a Comment